Canine Parvovirus Infection

Canine parvovirus infection is a highly contagious, acute, and often fatal viral disease caused by canine parvovirus type 2 (CPV-2), a small, non-enveloped, single-stranded DNA virus belonging to the family Parvoviridae, genus Protoparvovirus. The disease primarily affects dogs, especially puppies and unvaccinated young adults, and is characterized by severe hemorrhagic gastroenteritis, profound leukopenia, and immunosuppression. The virus has a high affinity for rapidly dividing cells, particularly intestinal crypt epithelium, bone marrow progenitor cells, and lymphoid tissues, leading to villous atrophy, malabsorption, and secondary bacterial translocation. In neonatal puppies, CPV-2 can also cause myocarditis, although this is less common with current strains. The disease is a major cause of morbidity and mortality in shelters and kennels, with a case fatality rate of up to 91% in untreated cases, but with prompt and aggressive therapy, survival rates can exceed 80%. The virus is extremely stable in the environment, resistant to many common disinfectants, and can persist for months to years, facilitating transmission via fomites, contaminated surfaces, and even the hands of handlers. Vaccination remains the cornerstone of prevention, with modified-live vaccines providing long-lasting immunity. The clinical course is typically acute, with incubation period of 3-7 days, and clinical signs include lethargy, anorexia, vomiting, and profuse, often hemorrhagic, diarrhea. Early diagnosis and intensive supportive care are critical for a favorable outcome.

The causative agent is canine parvovirus type 2 (CPV-2), a non-enveloped, icosahedral virus with a single-stranded DNA genome of approximately 5,200 nucleotides. CPV-2 emerged in the late 1970s as a host-range variant of feline panleukopenia virus (FPV) or a closely related parvovirus. Since its emergence, several antigenic variants have been identified: CPV-2a, CPV-2b, and CPV-2c, which differ in amino acid sequences in the capsid protein VP2. These variants have replaced the original CPV-2 and are now distributed worldwide. CPV-2c is particularly prevalent in some regions and may be associated with more severe clinical signs, although this is debated. The virus is highly stable in the environment, resistant to heat (56°C for 60 minutes), many disinfectants (e.g., quaternary ammonium compounds, alcohol), and can survive in organic material for months. It is transmitted primarily via the fecal-oral route, through direct contact with infected dogs or indirect contact with contaminated fomites (e.g., food bowls, bedding, shoes, hands). The virus is shed in feces in high concentrations (up to 10^9 TCID50/g) from 3-4 days post-infection and can be shed for up to 2-3 weeks after clinical recovery. The virus initially replicates in the oropharynx and lymphoid tissues (tonsils, mesenteric lymph nodes), then spreads hematogenously to other rapidly dividing tissues, including intestinal crypt epithelium, bone marrow, and lymphoid organs. The molecular trigger for disease is the viral capsid protein VP2, which binds to the transferrin receptor (TfR) on host cells, facilitating entry. The virus requires host DNA polymerase for replication, as it does not encode its own polymerase, and thus targets cells in the S-phase of the cell cycle. The cytopathic effect is due to viral replication and apoptosis of infected cells, leading to tissue destruction and clinical disease.

Canine parvovirus infection occurs worldwide and affects all breeds of dogs, but certain breeds such as Rottweilers, Doberman Pinschers, Pit Bulls, and German Shepherds are reported to have increased susceptibility and more severe disease, possibly due to genetic factors affecting immune response or TfR expression. The disease is most common in puppies between 6 weeks and 6 months of age, with a peak incidence at 2-4 months, coinciding with the waning of maternal antibody and before completion of the vaccination series. Unvaccinated or incompletely vaccinated dogs are at highest risk. The virus is endemic in many environments, particularly in shelters, breeding kennels, and dog parks, where high population density and environmental contamination facilitate transmission. There is no sex predilection. Seasonality is not pronounced, but outbreaks may be more common in warmer months when puppies are more likely to be outdoors and in contact with other dogs. The incidence has decreased significantly in developed countries due to widespread vaccination, but outbreaks still occur in unvaccinated populations and in areas with low vaccination coverage. The virus is highly contagious, with an estimated basic reproduction number (R0) of 1.5-2.0 in susceptible populations. Environmental contamination is a major factor in transmission, as the virus can survive for months in soil and on surfaces, and is resistant to many common disinfectants, including alcohol and quaternary ammonium compounds. Effective disinfectants include bleach (sodium hypochlorite) at a dilution of 1:30, potassium peroxymonosulfate, and accelerated hydrogen peroxide. The virus is also resistant to heat and freezing. In shelters, outbreaks can be devastating, with high morbidity and mortality, and require strict isolation and decontamination protocols.

The pathophysiology of canine parvovirus infection involves a complex interplay of viral replication, immune response, and secondary bacterial invasion. After oral or nasal inoculation, the virus replicates in the oropharynx and regional lymphoid tissues (tonsils, retropharyngeal lymph nodes) within 18-24 hours. A primary viremia occurs at 2-3 days post-infection, disseminating the virus to other lymphoid tissues and to the intestinal crypt epithelium, bone marrow, and, in neonates, the myocardium. The virus targets cells in the S-phase of the cell cycle, as it requires host cell DNA polymerase for replication. In the intestine, the virus infects and destroys the rapidly dividing crypt epithelial cells, leading to crypt necrosis and villous atrophy. The loss of absorptive epithelial cells results in malabsorption, and the denuded mucosa allows leakage of blood and protein into the lumen, causing hemorrhagic diarrhea and protein-losing enteropathy. The destruction of the intestinal barrier also permits translocation of bacteria and endotoxins into the bloodstream, leading to sepsis and systemic inflammatory response syndrome (SIRS). In the bone marrow, the virus infects and destroys hematopoietic progenitor cells, causing leukopenia, particularly lymphopenia and neutropenia, which exacerbates immunosuppression and increases susceptibility to secondary infections. Lymphoid tissues, including the thymus, spleen, and lymph nodes, undergo necrosis and depletion of lymphocytes, further compromising the immune response. The release of pro-inflammatory cytokines (e.g., TNF-α, IL-1, IL-6) contributes to systemic effects, including fever, lethargy, and shock. In neonatal puppies (<4 weeks), the virus can infect myocardial cells, causing acute myocarditis and heart failure, often without enteric signs. The clinical outcome depends on the age, immune status, and the presence of secondary infections. Recovery is associated with the regeneration of intestinal crypts and the development of a humoral immune response, which typically occurs within 5-7 days after infection. The virus is shed in feces for up to 2-3 weeks after recovery, and the immune response is protective against reinfection.

Several factors predispose dogs to canine parvovirus infection and severe disease. Age is the most significant risk factor, with puppies between 6 weeks and 6 months being most susceptible, as they have declining maternal antibody titers and an immature immune system. Maternal antibodies can interfere with vaccination, leading to a window of susceptibility. Breed predisposition has been reported, with Rottweilers, Doberman Pinschers, Pit Bulls, and German Shepherds showing increased susceptibility and severity, possibly due to genetic variations in the transferrin receptor or immune response genes. Stress factors, such as weaning, overcrowding, poor nutrition, and concurrent infections (e.g., intestinal parasites, coronavirus), can exacerbate the disease. Immunosuppression from any cause, including concurrent viral infections (e.g., canine distemper virus), corticosteroid therapy, or other immunosuppressive drugs, increases the risk. Lack of vaccination or incomplete vaccination is a major risk factor. Environmental factors, such as high dog density in shelters or kennels, poor hygiene, and contaminated fomites, facilitate transmission. The virus is highly stable in the environment, and inadequate disinfection can lead to persistent contamination. Additionally, the presence of other pathogens, such as Clostridium perfringens or Salmonella spp., can worsen the clinical signs and outcome. Management practices, such as early weaning and early rehoming of puppies, can increase exposure to the virus. Finally, the immune status of the dam influences the level of maternal antibody transferred to puppies, and puppies from unvaccinated or poorly vaccinated dams are at higher risk.

The clinical signs of canine parvovirus infection typically appear 3-7 days after exposure and can range from subclinical to peracute fatal disease. The most common presentation is acute gastroenteritis, with lethargy, anorexia, vomiting, and diarrhea. Vomiting often precedes diarrhea and may be bilious or contain blood. Diarrhea is typically profuse, foul-smelling, and may be hemorrhagic, ranging from mucoid to watery with frank blood. Fever is common, but hypothermia may occur in severe cases due to shock. Dehydration and electrolyte imbalances develop rapidly due to fluid losses. Abdominal pain is often present, and palpation may reveal fluid-filled, gas-distended loops of intestine. In peracute cases, dogs may present in shock with collapse, severe depression, and cardiovascular collapse, sometimes without prior gastrointestinal signs. In neonatal puppies (<4 weeks), myocarditis may occur, leading to acute respiratory distress, cyanosis, and sudden death, often without enteric signs. The clinical course can be divided into stages: peracute (sudden death), acute (classic signs), and subacute (recovery or complications). Systemic signs include tachycardia, weak pulses, prolonged capillary refill time, and pale mucous membranes due to dehydration and sepsis. Secondary bacterial infections, such as pneumonia or urinary tract infections, may develop due to immunosuppression. In some cases, neurological signs have been reported, but these are rare and may be due to secondary metabolic disturbances. The severity of clinical signs is variable, and some dogs may have mild, self-limiting diarrhea. However, without treatment, the disease is often fatal, with mortality rates up to 91% in untreated cases. With aggressive therapy, survival rates exceed 80%.

The differential diagnoses for canine parvovirus infection include other causes of acute gastroenteritis and hemorrhagic diarrhea in dogs. Key differentials include: 1) Canine coronavirus infection: Causes mild to moderate gastroenteritis, typically less severe than CPV, with no leukopenia; diagnosis by PCR or serology. 2) Canine distemper virus: Can cause gastrointestinal signs, but also respiratory and neurological signs; diagnosis by PCR, serology, or histopathology. 3) Salmonellosis: Bacterial enteritis due to Salmonella spp., often associated with contaminated food; diagnosis by fecal culture or PCR. 4) Campylobacteriosis: Bacterial enteritis due to Campylobacter jejuni, causing diarrhea, often with blood; diagnosis by fecal culture or PCR. 5) Giardiasis: Protozoal infection causing diarrhea, often with mucus, but not typically hemorrhagic; diagnosis by fecal antigen test or microscopy. 6) Intestinal intussusception: Mechanical obstruction causing vomiting, abdominal pain, and bloody diarrhea; diagnosis by ultrasound or barium contrast radiography. 7) Hemorrhagic gastroenteritis (HGE): Acute, often severe, hemorrhagic diarrhea with hemoconcentration (elevated PCV), but no leukopenia; etiology unknown, possibly Clostridium perfringens; diagnosis by exclusion and response to therapy. 8) Foreign body ingestion: Can cause vomiting and diarrhea, but often with abdominal pain and obstruction; diagnosis by imaging. 9) Toxin exposure (e.g., garbage toxicity, heavy metals): Can cause gastroenteritis; history of exposure and toxicology screening. 10) Inflammatory bowel disease (IBD): Chronic, not acute, but can have acute flares; diagnosis by biopsy. To rule out these differentials, a combination of history, physical examination, hematology (leukopenia is highly suggestive of CPV), fecal testing (CPV antigen ELISA or PCR), and imaging (abdominal radiographs/ultrasound) is used. Definitive diagnosis of CPV is based on detection of viral antigen in feces or viral DNA by PCR.

The diagnostic algorithm for canine parvovirus infection begins with a thorough history and physical examination, focusing on signalment (age, vaccination status), exposure history, and clinical signs (vomiting, diarrhea, lethargy). Initial assessment includes vital signs, hydration status, and abdominal palpation. If CPV is suspected, the following steps are recommended: 1) Point-of-care fecal antigen test (ELISA) for CPV: This is a rapid, sensitive, and specific test that can be performed in-house. A positive result confirms the diagnosis, but a negative result does not rule out CPV, especially early in the infection or if the dog has been vaccinated recently (modified-live vaccine can cause false positives for up to 2 weeks). 2) Complete blood count (CBC): Leukopenia (especially lymphopenia and neutropenia) is a hallmark finding, but may not be present in early or mild cases. 3) Serum biochemistry and electrolyte panel: To assess hydration, electrolyte imbalances (hypokalemia, hyponatremia), acid-base status, and organ function (renal, hepatic). 4) Fecal PCR: Highly sensitive and specific, can detect viral DNA even in low amounts, and can differentiate vaccine strains from field strains. 5) Abdominal imaging (radiographs or ultrasound): To rule out other causes of vomiting/diarrhea, such as intussusception or foreign body. 6) If the dog is critically ill, additional tests may include blood gas analysis, lactate measurement, and coagulation profile. 7) In cases of sudden death or for confirmation, necropsy with histopathology and immunohistochemistry can be performed. The diagnostic algorithm should be adapted based on the clinical status and available resources. In a shelter or outbreak situation, early diagnosis is crucial for implementing isolation and decontamination protocols. A positive fecal antigen test in a dog with compatible clinical signs is sufficient for a presumptive diagnosis, and treatment should be initiated immediately.

Laboratory findings in canine parvovirus infection are characteristic and aid in diagnosis and monitoring. Hematology: The most consistent finding is leukopenia, with a decrease in total white blood cell count, particularly lymphocytes and neutrophils. Neutropenia is often severe (<2,000/μL) and may be associated with a left shift or toxic changes. Lymphopenia is also common. In some cases, the leukopenia may be followed by a rebound leukocytosis during recovery. Anemia may be present due to blood loss from hemorrhagic diarrhea, but is often mild initially. Thrombocytopenia can occur, but is usually not severe. Serum Biochemistry: Dehydration leads to prerenal azotemia (elevated BUN and creatinine), and electrolyte imbalances are common, including hyponatremia, hypokalemia, and hypochloremia due to vomiting and diarrhea. Metabolic acidosis is frequent due to bicarbonate loss in diarrhea and lactic acidosis from poor tissue perfusion. Hypoglycemia may occur in puppies due to decreased intake and increased metabolic demands. Total protein may be low due to protein-losing enteropathy. Liver enzymes (ALT, AST) may be mildly elevated due to hepatic hypoxia or inflammation. Urinalysis: Usually unremarkable, but may show concentrated urine (high specific gravity) due to dehydration. Blood Gas Analysis: Metabolic acidosis with low bicarbonate and base deficit is common. Specific Biomarkers: C-reactive protein (CRP) is often elevated, reflecting systemic inflammation. Fecal antigen testing (ELISA) is the most common specific test, with high sensitivity and specificity. PCR on feces or blood is more sensitive and can be used for confirmation, especially in early infection or when ELISA is negative. Serology (antibody titers) is not useful for acute diagnosis, as it reflects prior exposure or vaccination. In cases of myocarditis, cardiac biomarkers such as troponin I may be elevated. Overall, the combination of leukopenia, hemorrhagic diarrhea, and a positive fecal antigen test is highly suggestive of CPV infection.

Imaging findings in canine parvovirus infection are non-specific but can help rule out other causes of acute abdomen and assess complications. Abdominal radiographs may show gas-filled, dilated loops of small intestine, consistent with ileus or enteritis. In cases of intussusception, a soft tissue mass or target sign may be visible. Free abdominal fluid may be seen in cases of perforation or severe protein-losing enteropathy. Thoracic radiographs are usually unremarkable, but may show signs of aspiration pneumonia if vomiting is severe. Abdominal ultrasonography is more sensitive and can reveal thickened intestinal walls, loss of normal layering, and hyperechoic mucosal striations due to necrosis. The small intestine may be fluid-filled and hypomotile. Mesenteric lymph nodes may be enlarged and hypoechoic. Ultrasonography is also useful for detecting intussusception, which is a potential complication. In cases of myocarditis, echocardiography may reveal decreased myocardial contractility, dilated chambers, and increased echogenicity of the myocardium. However, imaging is not essential for diagnosis, and treatment should not be delayed for imaging if CPV is strongly suspected. Advanced imaging such as CT or MRI is rarely indicated, but may be used to evaluate for complications such as intussusception or perforation. Endoscopy is not typically performed in the acute setting due to the risk of perforation and the need for anesthesia, but if performed, it may show erythematous, edematous, and ulcerated mucosa in the duodenum and jejunum.

Cytology and histopathology are not commonly used for antemortem diagnosis of canine parvovirus infection, but they can be helpful in postmortem confirmation or in atypical cases. Fine needle aspirates of mesenteric lymph nodes may show lymphoid depletion and necrosis, but this is non-specific. Fecal cytology may reveal red blood cells and inflammatory cells, but is not diagnostic. Histopathology of the small intestine is characteristic: the intestinal crypts are dilated and necrotic, with loss of villous epithelium and villous atrophy. The lamina propria is infiltrated with mononuclear cells and neutrophils, and there may be hemorrhage and edema. Intranuclear inclusion bodies may be seen in crypt epithelial cells, but are not always present. Immunohistochemistry (IHC) using antibodies against CPV antigens can confirm the presence of virus in tissues. In the bone marrow, there is depletion of hematopoietic cells, and in lymphoid tissues, there is lymphoid depletion and necrosis. In cases of myocarditis, histopathology shows myocardial necrosis and mononuclear infiltration, with intranuclear inclusion bodies in myocardial fibers. Electron microscopy can also be used to visualize viral particles. In a clinical setting, histopathology is rarely performed antemortem due to the invasiveness and the availability of less invasive diagnostic tests. However, in cases of sudden death or when the diagnosis is uncertain, necropsy with histopathology and IHC is valuable for confirming CPV and ruling out other causes.

Treatment of canine parvovirus infection is primarily supportive and symptomatic, as there is no specific antiviral therapy. The main goals are to maintain hydration and electrolyte balance, control vomiting and diarrhea, prevent and treat secondary bacterial infections, and provide nutritional support. Hospitalization is recommended for all but the mildest cases. Fluid therapy is the cornerstone of treatment: crystalloids (e.g., lactated Ringer's solution or Normosol-R) are administered intravenously at a rate to correct dehydration (typically 5-10% of body weight) and then to maintain hydration (maintenance rate of 40-60 ml/kg/day, adjusted for ongoing losses). Colloids (e.g., hetastarch) may be used in cases of hypoalbuminemia or hypovolemic shock. Electrolyte imbalances, especially hypokalemia, should be corrected by adding potassium chloride to fluids (e.g., 20-40 mEq/L). Dextrose may be added if hypoglycemia is present. Antiemetics are indicated to control vomiting: maropitant (Cerenia) at 1 mg/kg IV or SC once daily, or metoclopramide at 1-2 mg/kg/day as a continuous rate infusion (CRI). Antacids such as famotidine (0.5-1 mg/kg IV or PO q12h) or omeprazole (0.7-1 mg/kg PO q24h) may be used to reduce gastric acidity. Antibiotics are recommended to prevent or treat secondary bacterial translocation and sepsis: broad-spectrum coverage is needed, such as ampicillin (20-30 mg/kg IV q8h) combined with enrofloxacin (5-10 mg/kg IV or SC q24h) or amikacin (15-20 mg/kg IV or SC q24h) in severe cases, but caution with aminoglycosides in dehydrated dogs. Alternatively, a third-generation cephalosporin like cefovecin (8 mg/kg SC once) or cefotaxime (25-50 mg/kg IV q8h) can be used. Probiotics may be beneficial, but evidence is limited. Nutritional support is important: early enteral feeding (within 24-48 hours) has been shown to improve outcomes. A highly digestible, low-fat diet can be offered in small, frequent meals, or a feeding tube (nasoesophageal or esophagostomy) may be placed if the dog is anorexic. Parenteral nutrition may be considered in severe cases. Additional therapies include anti-endotoxic agents (e.g., polymyxin B) and immunomodulators (e.g., recombinant feline interferon-omega at 2.5 MU/kg IV once daily for 3 days) have shown some benefit in reducing mortality. Pain management may be needed for abdominal pain, using opioids such as buprenorphine (0.01-0.02 mg/kg IV or IM q8-12h) or fentanyl CRI. Nursing care includes keeping the dog clean and warm, and monitoring vital signs and body weight. In cases of severe anemia or coagulopathy, blood transfusions may be necessary. The duration of hospitalization is typically 3-7 days, and discharge is based on clinical improvement, ability to eat and drink, and resolution of vomiting.

The prognosis for canine parvovirus infection is guarded to good, depending on several factors. Without treatment, the mortality rate is high, up to 91%. With aggressive supportive care, survival rates exceed 80% in most studies. Factors associated with a poorer prognosis include: young age (<6 months), severe leukopenia (especially neutropenia <1,000/μL), hypothermia, severe dehydration, presence of sepsis or systemic inflammatory response syndrome (SIRS), high body weight loss, and delayed presentation to veterinary care. The presence of concurrent infections or comorbidities also worsens the prognosis. In a study, dogs that survived had significantly higher lymphocyte counts and lower CRP levels at admission. The duration of clinical signs before treatment is also important; early intervention improves outcomes. The prognosis for puppies with myocarditis is very poor, with high mortality. However, most dogs that survive the acute phase recover fully, with no long-term sequelae. Some dogs may develop chronic gastrointestinal issues, such as inflammatory bowel disease, but this is not well documented. Reinfection is rare due to the development of a strong humoral immune response. The prognosis is also influenced by the availability of intensive care facilities and the expertise of the veterinary team. In shelter settings, the prognosis may be worse due to limited resources and high stress. Overall, with prompt and appropriate treatment, the majority of dogs can be expected to recover.

Follow-up care for dogs recovering from canine parvovirus infection is important to ensure complete recovery and to prevent complications. After discharge, the dog should be isolated from other dogs for at least 2-3 weeks, as they can continue to shed the virus in feces. The owner should be advised to disinfect the environment thoroughly with a bleach solution (1:30 dilution) or other parvovirus-effective disinfectants. A recheck appointment is typically scheduled 7-14 days after discharge to assess clinical status, weight, and hydration. A complete blood count may be repeated to monitor the resolution of leukopenia and the return of normal white blood cell counts. Serum biochemistry may be repeated if there were significant abnormalities. The dog should be fed a highly digestible diet in small, frequent meals for at least a week, and then gradually transitioned to a normal diet. Probiotics may be continued for a few weeks to help restore the intestinal microbiota. Vaccination should be resumed according to the veterinarian's recommendation, typically starting 2-4 weeks after recovery, as the dog's immune system is now capable of responding to vaccines. The owner should monitor for any signs of relapse or complications, such as chronic diarrhea, vomiting, or poor growth. In puppies, growth and development should be monitored. Long-term follow-up is generally not required, but if the dog develops chronic gastrointestinal signs, further investigation may be warranted. In cases of myocarditis, cardiac follow-up with echocardiography may be recommended. Overall, the prognosis for full recovery is excellent with appropriate care.

Clinical Pearls: 1) Always consider CPV in any unvaccinated or incompletely vaccinated puppy with acute vomiting and diarrhea, even if the fecal antigen test is negative; a negative test does not rule out CPV, especially early in the infection. 2) Leukopenia is a strong indicator of CPV, but its absence does not exclude the disease. 3) Early enteral nutrition (within 24-48 hours) has been shown to improve outcomes and should be initiated as soon as vomiting is controlled. 4) Use of maropitant is highly effective for controlling vomiting and may also have anti-inflammatory effects. 5) In shelters, immediate isolation of suspected cases and strict decontamination protocols are essential to prevent outbreaks. 6) Vaccination is the best prevention; ensure puppies receive a series of vaccines starting at 6-8 weeks of age, with boosters every 2-4 weeks until 16-20 weeks of age. 7) Consider the use of recombinant feline interferon-omega as an adjunctive therapy, as it has been shown to reduce mortality. 8) Monitor for intussusception, which can occur during recovery; if the dog's condition deteriorates after initial improvement, perform abdominal ultrasound. 9) Provide aggressive fluid therapy, as dehydration and electrolyte imbalances are major contributors to mortality. 10) Educate owners about the environmental stability of the virus and the need for proper disinfection. Clinical Pitfalls: 1) Do not delay treatment while waiting for diagnostic test results; if CPV is suspected, start supportive care immediately. 2) Avoid using NSAIDs or corticosteroids, as they can worsen gastrointestinal ulceration and immunosuppression. 3) Do not use aminoglycosides in dehydrated dogs without adequate fluid therapy, as they can cause nephrotoxicity. 4) Do not rely solely on fecal antigen testing; a negative result can occur in early infection or if the dog has been vaccinated recently (false positive). 5) Do not discharge the dog too early; ensure the dog is eating and drinking normally and has no vomiting for at least 24 hours. 6) Do not forget to monitor for hypoglycemia and hypokalemia, which are common and can be life-threatening. 7) Do not neglect to check for concurrent infections, such as intestinal parasites, which can worsen the disease. 8) Do not assume that a dog with mild signs does not need hospitalization; even mild cases can deteriorate rapidly. 9) Do not forget to disinfect the environment thoroughly, as the virus can survive for months. 10) Do not skip the follow-up vaccination schedule, as the dog may still be susceptible to other diseases.

The following drug protocols are based on Plumb's Veterinary Drug Handbook and current veterinary guidelines. All dosages are for dogs unless otherwise specified. 1) Fluid Therapy: Crystalloids (e.g., Lactated Ringer's Injection, Normosol-R) IV: Shock dose: 60-90 ml/kg IV over 15-30 minutes, then reassess; Maintenance: 40-60 ml/kg/day IV, adjusted for ongoing losses (vomiting, diarrhea). Add potassium chloride (KCl) 20-40 mEq/L to fluids if hypokalemia is present, not exceeding 0.5 mEq/kg/hour. Add dextrose 2.5-5% if hypoglycemia. Colloids (e.g., Hetastarch 6%): 10-20 ml/kg IV over 30-60 minutes for hypovolemic shock or hypoalbuminemia. 2) Antiemetics: Maropitant (Cerenia): 1 mg/kg IV or SC once daily; may be used for up to 5 days. Metoclopramide: 1-2 mg/kg/day as a continuous rate infusion (CRI) IV; or 0.2-0.4 mg/kg PO q8h. Ondansetron: 0.1-0.2 mg/kg IV or PO q8-12h (alternative). 3) Antacids: Famotidine: 0.5-1 mg/kg IV or PO q12h. Omeprazole: 0.7-1 mg/kg PO q24h. 4) Antibiotics: Ampicillin: 20-30 mg/kg IV q8h. Enrofloxacin: 5-10 mg/kg IV or SC q24h (do not exceed 5 mg/kg in puppies due to cartilage damage risk). Amikacin: 15-20 mg/kg IV or SC q24h (use with caution, monitor renal function). Cefovecin (Convenia): 8 mg/kg SC once, may be repeated in 14 days. Cefotaxime: 25-50 mg/kg IV q8h. Metronidazole: 10-15 mg/kg IV or PO q12h (for anaerobic coverage). 5) Antiviral/Immunomodulatory: Recombinant feline interferon-omega (Virbagen Omega): 2.5 MU/kg IV once daily for 3 consecutive days. 6) Probiotics: e.g., FortiFlora (Purina) or Proviable (Nutramax) PO once daily. 7) Analgesics: Buprenorphine: 0.01-0.02 mg/kg IV or IM q8-12h. Fentanyl CRI: 2-5 mcg/kg/hour IV. 8) Nutritional Support: If anorexic, place nasoesophageal or esophagostomy tube; use a highly digestible diet (e.g., Hill's i/d, Royal Canin Gastrointestinal) in small frequent meals. 9) Additional: Anti-endotoxic agents (e.g., polymyxin B) are not routinely recommended. Blood transfusion (packed red blood cells or whole blood) if PCV <20% or clinical signs of anemia. Plasma transfusion may be considered for hypoalbuminemia. All protocols should be adjusted based on the patient's clinical status, renal/hepatic function, and response to therapy. Contraindications: Avoid corticosteroids and NSAIDs. Drug interactions: Enrofloxacin may interact with antacids, reducing absorption; administer separately. Aminoglycosides should not be used with other nephrotoxic drugs.

The evidence base for canine parvovirus treatment is largely derived from retrospective and prospective studies, as well as expert consensus. Key findings include: 1) Fluid therapy is essential, and early aggressive fluid resuscitation improves survival (Prittie, 2004). 2) The use of maropitant has been shown to reduce vomiting and improve clinical scores (Sedlacek et al., 2015). 3) Early enteral nutrition (within 24-48 hours) is associated with improved outcomes, including faster weight gain and shorter hospitalization (Mohr et al., 2003). 4) Antibiotic use is recommended to prevent sepsis, but the choice of antibiotics should be based on the risk of bacterial translocation; a combination of ampicillin and enrofloxacin is commonly used (Schoeman, 2011). 5) Recombinant feline interferon-omega has been shown to reduce mortality in a randomized controlled trial (de Mari et al., 2003). 6) Probiotics may help restore intestinal flora, but evidence is limited (Gómez-Gallego et al., 2018). 7) The use of antiemetics, particularly maropitant, is supported by clinical trials (Sedlacek et al., 2015). 8) The prognosis is improved with early treatment and intensive care; mortality rates in treated dogs are typically 5-20% (Prittie, 2004). 9) Vaccination remains the most effective preventive measure, and modified-live vaccines provide long-lasting immunity (Schultz et al., 2010). 10) The ACVIM consensus statement on the diagnosis and management of canine parvovirus infection provides guidelines for diagnosis and treatment (Venn et al., 2017). Overall, the evidence supports a multimodal approach to therapy, with a focus on supportive care and early intervention.